- $23.61m
- $7.46m
- $52.55m
- 55
- 59
- 24
- 43
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.04 | ||
| Price to Tang. Book | 1.04 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.45 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -50.7% | ||
| Return on Equity | -72.72% | ||
| Operating Margin | -43.46% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 40.39 | 41.98 | 48.3 | 45.56 | 52.55 | 54.16 | 62.91 | 10.13% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Exagen Inc. is a provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision-making. The Company has developed and is commercializing a portfolio of testing products, under its AVISE brand. It commercially launched its testing product, AVISE CTD, which enables differential diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The comprehensive nature of AVISE CTD allows for the testing of various relevant biomarkers in one convenient blood draw. Included in AVISE CTD is its proprietary AVISE Lupus test, which enables the diagnosis of systemic lupus erythematosus (SLE) based on levels of erythrocyte bound C4d (EC4d) and B cell C4d (BC4d); along with anti-nuclear antibodies (ANA) and double-stranded DNA antibodies (ds-DNA). AVISE Lupus provides rheumatologists and their patients with sensitive and specific results.
Directors
- Brian Birk NEC (61)
- Fortunato Rocca PRE (59)
- Kamal Adawi CFO (42)
- Mark Hazeltine COO (47)
- Debra Zack OTH (64)
- Ana Hooker IND (54)
- Wendy Johnson IND (69)
- Tina Nova IND (67)
- Ebetuel Pallares IND (47)
- Bruce Robertson IND (58)
- James Tullis IND (73)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 17th, 2003
- Public Since
- September 19th, 2019
- No. of Shareholders
- 31
- No. of Employees
- 174
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 17,235,751
- Address
- 1261 Liberty Way Ste C, VISTA, 92081-8356
- Web
- https://exagen.com/
- Phone
- +1 7605601501
- Auditors
- BDO USA, LLP
Upcoming Events for XGN
Exagen Inc Annual Shareholders Meeting
Q2 2024 Exagen Inc Earnings Release
Similar to XGN
Airsculpt Technologies
NASDAQ Global Market
Biodesix
NASDAQ Global Market
Burning Rock Biotech
NASDAQ Global Market
Fulgent Genetics
NASDAQ Global Market
InterCure
NASDAQ Global Market
FAQ
What is the Exagen share price?
As of Today at 19:08 UTC, shares in Exagen are trading at $1.37. This share price information is delayed by 15 minutes.
How has the Exagen share price performed this year?
Shares in Exagen last closed at $1.37 and the price had moved by -44.08% over the past 365 days. In terms of relative price strength the Exagen share price has underperformed the S&P500 Index by -53.47% over the past year.
What are the analyst and broker recommendations for Exagen?
The overall consensus recommendation for Exagen is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Exagen dividend yield?
Exagen does not currently pay a dividend.
Does Exagen pay a dividend?
Exagen does not currently pay a dividend.
When does Exagen next pay dividends?
Exagen does not currently pay a dividend.
How do I buy Exagen shares?
To buy shares in Exagen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Exagen?
As of the previous close price of $1.37, shares in Exagen had a market capitalisation of $23.61m.
Where are Exagen shares listed?
Here are the trading details for Exagen:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: XGN
What kind of share is Exagen?
Based on an overall assessment of its quality, value and momentum Exagen is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Exagen share price forecast for 2024?
The analyst consensus target price for shares in Exagen is $5.50. That is 301.46% above the last closing price of $1.37.
Analysts covering Exagen currently have a consensus Earnings Per Share (EPS) forecast of -$1.37 for the next financial year.
What is the trend in the Exagen share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Exagen. Over the past six months, its share price has underperformed the S&P500 Index by -28.2%.
As of the last closing price of $1.37, shares in Exagen were trading -32.12% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Exagen PE Ratio?
The Exagen PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.37.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Exagen?
Exagen's management team is headed by:
- Brian Birk - NEC
- Fortunato Rocca - PRE
- Kamal Adawi - CFO
- Mark Hazeltine - COO
- Debra Zack - OTH
- Ana Hooker - IND
- Wendy Johnson - IND
- Tina Nova - IND
- Ebetuel Pallares - IND
- Bruce Robertson - IND
- James Tullis - IND